Anti-tgf-beta Antibody For The Treatment Of Fanconi Anemia


The present invention provides methods of treating, preventing or delaying the onset of bone marrow failure in Fanconi Anemia patients comprising administering to the patient a composition comprising a neutralizing anti-TGF-beta antibody, e.g. fresolimumab or 1D11.

Download PDF
Document Preview
Document History
  • Publication: Sep 1, 2016
  • Application: Feb 25, 2016
    WO US 2016/0019626 W
  • Priority: Feb 25, 2015
    US US 201562120596 P

Sign in to the Lens